# A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China

Study · id `cardio:ct-nct07900438` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07900438](<https://clinicaltrials.gov/study/NCT07900438>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07900438

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07900438. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-12 (actual); primary completion 2029-12-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07900438, source copy `cardio:ctgov-nct07900438-2026-10-28`, retrieved 2026-10-31)
- Started: 2026-10-12 (actual) (ClinicalTrials.gov record NCT07900438, source copy `cardio:ctgov-nct07900438-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2029-12-20 (anticipated) (ClinicalTrials.gov record NCT07900438, source copy `cardio:ctgov-nct07900438-2026-10-28`, retrieved 2026-10-31)
- Completion: 2030-01-24 (anticipated) (ClinicalTrials.gov record NCT07900438, source copy `cardio:ctgov-nct07900438-2026-10-28`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07900438, source copy `cardio:ctgov-nct07900438-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07900438-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
- Condition: Cardiovascular Risk
- Condition: Chronic Kidney Disease
- Intervention (Drug): Semaglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: bc5edc5d5aafd761039fc88eec63a1b28e8b169e30097b0a69a7f35e4f972793
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
